1. Scrip
  2. >>Business

Finance Watch: Biopharma IPOs Defy Broader Stock Performance Trends

 
• By Mandy Jackson

Public Company Edition: With returns for newly public biopharma companies rising, seven more jumped in line to go public in the US between the beginning of February and early March, while two drug developers launched IPOs in the EU. Meanwhile, already public companies keep raising gobs of cash.

Finance Watch

Since already-good returns for January's initial public offerings are rising, seven additional biopharmaceutical companies indicated their intention to launch IPOs in the US between early February and early March.

January's biopharma IPOs delivered an average return of 52.8% by Feb. 1 and the return for those seven companies grew to 63.7% as of March 1, besting by a wide...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business